SCHEMBL22284151

SCHEMBL22284151

Cc1cccc(C(C)NC(=O)c2nc3cc4c(-c5ccncc5)n[nH]c4cc3[nH]2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 16/20 0.54
MAPK3 P27361 7/20 0.54
LRRK2 Q5S007 1/20 0.41
ROCK1 Q13464 4/20 0.41
ROCK2 O75116 3/20 0.41
PRKG1 Q13976 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CHEK1 O14757 1/20 0.41
RPS6KA5 O75582 1/20 0.41
PRKCG P05129 1/20 0.41
CDK1 P06493 1/20 0.41
PRKACA P17612 1/20 0.41
RPS6KB1 P23443 1/20 0.41
CDK2 P24941 1/20 0.41
AKT2 P31751 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
IRAK1 P51617 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20931754 1.00 MAPK1 (0.54) MAPK1MAPK3LRRK2ROCK1ROCK2
SCHEMBL20931683 0.92 MAPK1 (0.55) MAPK1MAPK3LRRK2ROCK1ROCK2
SCHEMBL22284173 0.92 MAPK1 (0.55) MAPK1MAPK3LRRK2ROCK1ROCK2
SCHEMBL30554358 0.92 MAPK1 (0.55) MAPK1MAPK3LRRK2ROCK1ROCK2
SCHEMBL30554347 0.91 MAPK1 (0.53) MAPK1MAPK3ROCK1ROCK2PRKG1
SCHEMBL20916811 0.91 MAPK1 (0.53) MAPK1MAPK3ROCK1ROCK2PRKG1
SCHEMBL30554352 0.91 MAPK1 (0.53) MAPK1MAPK3ROCK1ROCK2PRKG1
SCHEMBL20931371 0.91 MAPK1 (0.53) MAPK1MAPK3ROCK1ROCK2PRKG1
SCHEMBL20916856 0.91 MAPK1 (0.53) MAPK1MAPK3ROCK1ROCK2PRKG1
SCHEMBL20931474 0.90 MAPK1 (0.54) MAPK1MAPK3LRRK2ROCK1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020200161-A1 SALT OF INDAZOLYL-CONTAINING TRICYCLIC DERIVATIVE AND CRYSTAL FORM THEREOF 上海翰森生物医药科技有限公司 2020-10-08 WO disclosed
EP-3699179-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2020-08-26 EP disclosed
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF MAPK1, MAPK11, MAPK14 MAPK1 1/4885MAPK3 14/4885LRRK2 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.